For research use only. Not for therapeutic Use.
NSAH is a reversible and competitive nonnucleoside ribonucleotide reductase (RR) inhibitor, with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively[1].
NSAH depresses dGTP and dATP levels in the dNTP pool causing S-phase arrest, providing evidence for RR inhibition in cells[1].
NSAH (0-10 μM, 2, 6, 24, or 72 h) exhibits potent anti-tumor activity in 3 cancer cell lines[1].
NSAH blocks S-phase progression well to the extent and timing of the decreases in dATP and dGTP[1].
| Catalog Number | I033545 |
| CAS Number | 1099592-35-4 |
| Synonyms | 2-hydroxy-N-[(E)-(2-hydroxynaphthalen-1-yl)methylideneamino]benzamide |
| Molecular Formula | C18H14N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H14N2O3/c21-16-8-4-3-7-14(16)18(23)20-19-11-15-13-6-2-1-5-12(13)9-10-17(15)22/h1-11,21-22H,(H,20,23)/b19-11+ |
| InChIKey | ZZSJOLDICPVVAV-YBFXNURJSA-N |
| SMILES | C1=CC=C2C(=C1)C=CC(=C2C=NNC(=O)C3=CC=CC=C3O)O |
| Reference | [1]. Md Faiz Ahmad, et al. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246. |
